DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Takeyama M, Nogami K, Matsumoto T, Noguchi-Sasaki M, Kitazawa T, Shima M.
An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
J Thromb Haemost 2020;
18 (04) 825-833
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.